Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ Ä¡·á ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, Áúȯº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Anti-vascular Endothelial Growth Factor Therapeutics Market Size, Share & Trends Analysis Report By Product (Eylea, Lucentis, Beovu), By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion), By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1611039
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 120 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,609,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 10,055,000
Printable PDF (5-User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,949,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ Ä¡·á ½ÃÀå ¼ºÀå ¹× µ¿Çâ

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, ¼¼°è Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ Ä¡·á ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 129¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È ¿¬Æò±Õ -2.35%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½Å¾à °³¹ßÀ» ÃËÁøÇϱâ À§ÇÑ Ç× VEGF Ä¡·áÁ¦ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÀÚ±Ý Áö¿ø Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈ­ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ¾È°ú Áúȯ¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ÀÇ Áõ°¡¿Í ÇÔ²² »õ·Î¿î Çõ½Å Á¦Ç°ÀÇ Ã¤ÅÃÀº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

À¯¿£ °æÁ¦»çȸ±¹ÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é 2019³â Àü ¼¼°è °í·ÉÀÚ(60¼¼ ÀÌ»ó)´Â ¾à 7¾ï 3õ¸¸ ¸íÀ¸·Î 65¼¼ ÀÌ»ó Àα¸ ºñÀ²Àº 6%¿´À¸¸ç, 2019³â¿¡´Â 9%·Î Áõ°¡Çß½À´Ï´Ù. °í·ÉÈ­ Àα¸¸¦ ±¹°¡º°·Î º¸¸é 2017³â ¾ÆÇÁ¸®Ä« ¾à 6,870¸¸ ¸í, ¾Æ½Ã¾Æ ¾à 5¾ï 4,920¸¸ ¸í, À¯·´ ¾à 1¾ï 8,300¸¸ ¸í, ºÏ¹Ì ¾à 7,840¸¸ ¸í, ¶óƾ¾Æ¸Þ¸®Ä« ¹× ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ¾à 7,600¸¸ ¸í ÀÌ»óÀ̾ú½À´Ï´Ù. µû¶ó¼­ ³ëÀÎ Àα¸ÀÇ Áõ°¡°¡ ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°³¹ßµµ»ó±¹ÀÇ °æ¿ì, ÀçÁ¤º¸Àü±Ý Á¦µµ°¡ ¾ø±â ¶§¹®¿¡ ºñ¿ë È¿À²ÀûÀÎ »õ·Î¿î ºÐÀÚ¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾È°ú ÀÇ»çµéÀÌ º¸´Ù È¿°úÀûÀÎ ½Å¾àÀ¸·Î ÀüȯÇÔ¿¡ µû¶ó ±â¾÷µéÀº »ê¾÷Àû ÁöÀ§¸¦ À¯ÁöÇϱâ À§ÇØ ¿¬±¸°³¹ß¿¡ ÅõÀÚÇÒ ¼ö¹Û¿¡ ¾ø´Â »óȲÀÔ´Ï´Ù. ±âÁ¸ ¾à¹°ÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯¿¡ ´ëÇÑ ¿¬±¸ÀÚµéÀÇ °ü½ÉÀº Ç×VEGF Ä¡·á ÆÄÀÌÇÁ¶óÀÎÀÇ ÁÖ¿ä Æ®·»µåÀÔ´Ï´Ù.

¶ÇÇÑ, °¢ ¾÷üµéÀº ÀÌ·¯ÇÑ Ä¡·áÁ¦ÀÇ Ã¤ÅÃÀ» Áõ°¡½Ãų ¼ö ÀÖ´Â ´Ù¾çÇÑ Á¦Çü°ú ¾à¹°Àü´Þ ½Ã½ºÅÛÀ» °³¹ßÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, F. Hoffmann-La Roche Ltd.´Â Æ÷Æ® Àü´Þ ½Ã½ºÅÛ-RG6321(¶ó´ÏºñÁÖ¸¿)À» °³¹ßÇϰí ÀÖÀ¸¸ç, ÇöÀç ÀÓ»ó 3»ó ½ÃÇèÀ» ÁøÇà ÁßÀÔ´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº ¸®ÇÊ °¡´ÉÇÑ ¾È±¸ ÀÓÇöõÆ®·Î, ¸ÂÃãÇü Á¦ÇüÀÇ ¶ó´ÏºñÁÖ¸¿À» ¼ö°³¿ù¿¡ °ÉÃÄ Áö¼ÓÀûÀ¸·Î Åõ¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ƯÇã º¸È£ÀÇ »ó½ÇÀº ½ÃÀå ¼ºÀå¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °¡´É¼ºÀÌ ³ôÀ¸¸ç, ÁÖ¿ä ±â¾÷µéÀº »õ·Î¿î ¼öÀÍ¿øÀ» ¸ð»öÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ±× °á°ú, ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰ »ý»ê¾÷üµéÀÌ »õ·Î¿î ½ÃÀåÀ» Çü¼ºÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °æÀïÀÇ ½ÉÈ­´Â ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª °æÀï ¿ìÀ§¸¦ °¡Áø ½ÅÁ¦Ç°ÀÇ Ãâ½Ã·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È ÀÌ·¯ÇÑ °æÀïÀÇ ¿µÇâÀº °¨¼ÒÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ Ä¡·á ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ Ä¡·á ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ Ä¡·á ½ÃÀå : Á¦Ç°º°, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ Ä¡·á ½ÃÀå : Áúȯº°, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå Ç×Ç÷°ü³»ÇǼ¼Æ÷¼ºÀåÀÎÀÚ Ä¡·á ½ÃÀå : Áö¿ªº°, ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå °æÀï ±¸µµ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Anti-Vascular Endothelial Growth Factor Therapeutics Market Growth & Trends:

The global anti-vascular endothelial growth factor therapeutics market size is expected to reach USD 12.90 billion by 2030, registering a CAGR of -2.35% over the forecast period, according to a new report by Grand View Research, Inc. Increased funding for R&D of anti-VEGF therapeutics to boost the development of new drugs is expected to accelerate market growth. Moreover, the introduction of novel innovative products coupled with the increasing geriatric population that is susceptible to develop ophthalmic diseases is expected to propel the market growth over the forecast period.

According to the United Nations Department of Economic and Social Affairs data, the global elderly population (aged 60 years and above) was around 703 million in 2019. The share of the population aged 65 years and above was 6%, which increased to 9% in 2019. The aging population, based on countries, was around 68.7 million in Africa, 549.2 million in Asia, 183 million in Europe, 78.4 million in North America, and more than 76 million in Latin America & other regions in 2017. Hence, the increasing geriatric population is anticipated to drive the market.

The lack of reimbursement policies in developing regions is creating an opportunity for cost-effective novel molecules. In addition, ophthalmologists switching to more effective newly launched drugs has compelled companies to invest in R&D to maintain their industry position. The interest of investigators on biosimilar of existing drugs is a major trend in the pipeline of anti-VEGF therapeutics.

Moreover, companies are developing various formulations and drug delivery systems that may increase the adoption of these therapies. For instance, F. Hoffmann La Roche Ltd. is developing the port delivery system-RG6321 (Ranibizumab)-which is currently undergoing a phase III clinical trial. It is an eye implant that is refillable and continuously delivers a customized formulation of ranibizumab over a period of months.

Loss of patent protection is likely to have a negative impact on the market growth and has led big pharma companies to consider new revenue streams. However, this is creating an emerging market for biosimilar drug producers in the space. This rising competition is anticipated to impede market growth. However, the launch of novel products with a competitive advantage is anticipated to lower the impact of the restraint during the forecast period.

Anti-vascular Endothelial Growth Factor Therapeutics Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Anti-Vascular Endothelial Growth Factor Therapeutics Market Variables, Trends & Scope

Chapter 4. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Product Estimates & Trend Analysis

Chapter 5. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Disease Estimates & Trend Analysis

Chapter 6. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Regional Estimates & Trend Analysis

Chapter 7. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â